Fresenius completes mAbxience deal while Fresenius stock sits 14.95 percent below its 52-week high

Published on 10/20/2026 at 10:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 45.04 on October 20, 2026, versus the EUR 44.91 Xetra close.

Deal and earnings context

Fresenius completed the mAbxience transaction for up to EUR 750 million on October 1, 2026.
Second-quarter 2026 revenue reached EUR 5.864 billion, up 6.00 percent organically.
Fresenius stock was trading at EUR 45.04 at 10:05 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.29 percent above the Xetra close of October 19, 2026.
Fresenius plans to publish third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 45.04 at Lang & Schwarz on October 20, 2026 at 10:05 a.m. CEST, up EUR 0.13, or 0.29 percent, versus the Xetra close of October 19, 2026 at EUR 44.91. The latest company catalyst is the completion of the mAbxience transaction announced on October 1, 2026.

Why the deal matters

According to finanzen.net, Fresenius acquired the remaining 45 percent of mAbxience for up to EUR 750 million, including a contingent EUR 50 million payment tied to site approvals. The transaction was signed and completed on September 30, 2026, and the company expects it to contribute immediately to group core earnings per share.

The purchase gives Fresenius full ownership of a biosimilars platform with four products on the market and eight development candidates. The release also said net debt to EBITDA should rise by around 20 basis points, while full-year leverage is expected to remain toward the lower end of the 2.5x to 3.0x target corridor.

What does full ownership change?

The strategic value lies in control over manufacturing capacity, investment decisions and launch timing. The acquired platform generated more than EUR 320 million in revenue in fiscal year 2025 and operates three production facilities, according to the company release.

Three steps since September

Fresenius invested EUR 54 million in European intravenous production capacity on September 25, 2026, sold 7.8 million Fresenius Medical Care shares for around EUR 300 million on September 7, 2026, and completed the EUR 750 million mAbxience transaction on October 1, 2026.

What comes next after 6.00 percent growth?

Fresenius reported second-quarter 2026 revenue of EUR 5.864 billion, up 6.00 percent organically, while group EBIT rose 10.00 percent to EUR 719 million and core net income increased 14.00 percent to EUR 470 million, according to its investor-relations overview. The company has scheduled its third-quarter 2026 results for November 4, 2026.

Stock remains below its yearly high

At EUR 45.04, the stock stood 14.95 percent below its 52-week high of EUR 52.96 and above its 52-week low of EUR 35.11. The price action was modest, so the mAbxience deal and the operating figures provide the stronger investor context.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.